Providing a diverse range of perspectives from bullish to bearish, 4 analysts have published ratings on Ovid Therapeutics (NASDAQ:OVID) in the last three months.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 1 1 0 0 Last 30D 0 0 1 0 0 1M Ago 2 0 0 0 0 2M Ago 0 1 0 0 0 3M Ago 0 0 0 0 0Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $7.38, along with a high estimate of $9.00 and a low estimate of $3.50. This upward trend is evident, with the current average reflecting a 84.5% increase from the previous average price target of $4.00.
Breaking Down Analyst Ratings: A Detailed ExaminationIn examining recent analyst actions, we gain insights into how financial experts perceive Ovid Therapeutics. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Yigal Nochomovitz Citigroup Lowers Neutral $3.50 $4.00 Kalpit Patel B. Riley Securities Announces Buy $9.00 - Raghuram Selvaraju HC Wainwright & Co. Announces Buy $9.00 - Laura Chico Wedbush Announces Outperform $8.00 - Key Insights: Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Ovid Therapeutics. ...Full story available on Benzinga.com
https://Benzinga.com